Curbing phone addiction: Desi, physical games to challenge e-game fixation at UP govt primary schools
The initiative, aligned with the National Education Policy (NEP) 2020, aims to encourage physical activity and reduce children's screen time by promoting indigenous games like Posham Pa and Langdi Taang.
The calendar, prepared by experts from the State Institute of Education (SIE), Prayagraj—a unit of the State Council of Educational Research and Training (SCERT)—has been distributed digitally to around 1.5 lakh schools across the state, for the benefit of over 1.5 crore students.
'The illustrated PDF calendar has been shared with school principals, who have been instructed to incorporate these games into teacher-parent meetings and other school events to actively engage children,' said Anil Kumar, principal in-charge, SIE-Prayagraj.
This initiative is a step toward reviving traditional games and improving both mental and physical health among students, he added.
Officials hope the games will not only promote fitness and teamwork but also instill cultural pride among young learners.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
2 hours ago
- Time of India
Why are Indian households struggling with medical costs despite health initiatives?
India had one of the highest out-of pocket (OOP) health expenditures as a percentage of total health expenditure among major economies in 2024, despite a decline from over 60% in 2014 to under 40% estimated in 2024. At the same time China's OOP share dropped slightly from over 36% to 32% over the same period. HEALTH PROTECTION GAP Widened by 21% since 2017 in emerging Asia. China alone accounts for nearly half the region's gap Key Drawback: Rising medical costs from 2017 Reasons:Gaps in coverage and access Agencies Explore courses from Top Institutes in Please select course: Select a Course Category Degree Product Management Artificial Intelligence healthcare Data Science Design Thinking Project Management Data Science Cybersecurity MCA others Data Analytics Management Digital Marketing Leadership Healthcare Operations Management Technology MBA CXO Public Policy Finance Others PGDM Skills you'll gain: Data-Driven Decision-Making Strategic Leadership and Transformation Global Business Acumen Comprehensive Business Expertise Duration: 2 Years University of Western Australia UWA Global MBA Starts on Jun 28, 2024 Get Details by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Knee pain prices might surprise you Knee pain | search ads Find Now Undo 2024 More Indian households experienced difficulty in affording medical costs Despite initiaitives like Ayushman Bharat (2018) and various state insurance schemes, gaps in coverage remain in India Low disposable incomes and inadequate public health infrastructure leave uninsured households vulnerable
The Hindu
5 hours ago
- The Hindu
RSS arm seeks clarity on draft guidelines on biosimilars
Swadeshi Jagran Manch (SJM), economic wing of the Rashtriya Swayamsewak Sangh (RSS), urged the Central Drugs Standard Control Organisation (CDSCO), the apex drug regulatory authority, to bring more clarity in its draft guidelines to ensure production of high-quality and cost-effective biosimilars in the country. In a letter to the Director General of CDSCO, SJM sought safeguards for the Indian industry from 'international pressures for regulations' that favour multi-national pharma companies. The CDSCO had recently issued the 2025 draft guidelines on similar biologics, also called biosimilars. 'Though the draft guidelines represent a pivotal advancement in making affordable, life-saving biosimilars accessible to millions of Indians suffering from chronic and life-threatening conditions such as cancer, diabetes, and autoimmune disorders it requires more clarity and direction,' the SJM letter reads. The SJM appreciated the draft guidelines for embracing the '3Rs principle' (replacement, reduction, refinement) as it reflects India's commitment to ethical scientific practices and alignment with global standards for animal welfare. Modern technologies, including in-vitro assays, organ-on-chip models, and computational simulations, provide robust, accurate, and humane alternatives to confirm the safety and biosimilarity of these drugs, it said. 'These methods are often faster and more precise than animal studies, reducing both ethical concerns and development costs,' it added. The organisation, however, noted that the guidelines stipulating that it will be the discretion of the CDSCO to decide whether a requirement of 'additional non-clinical in vivo animal studies' should be waived or not, poses a 'risk' of increasing biosimilar development cost. This provision goes against the practices of the leading regulatory authorities in other countries, it added. 'Prominent regulatory authorities like the UK MHRA, European Medicine Agency (EMA) Health Canada, and USFDA have either eliminated or phased out mandatory animal testing for biosimilars,' SJM said, adding its recommendation that waiving animal studies entirely when comprehensive laboratory tests demonstrate high similarity between a biosimilar and its reference product. Recently, civil societies, in a letter to CDSCO on the draft guidelines on biosimilars, has urged that there is an urgent need to eliminate unnecessary animal studies, and establish clear conditions for requiring comparative clinical trials for affordable biosimilars without compromising safety and efficacy. According to the SJM, the draft guidelines' provision to waive certain clinical trials when biosimilarity is established through analytical and functional studies is a forward-thinking measure, saying this approach can significantly reduce development costs and expedite market entry, which is critical for patients awaiting affordable treatments. However, the lack of explicit criteria in the guidelines for when waivers are permitted introduces ambiguity, potentially leading to inconsistent application and delays as well as 'room for corrupt practices', it said, stressing the need to establish 'clear conditions' for conduct of clinical trials.
Economic Times
7 hours ago
- Economic Times
Medtech firms flag inflated MRPs on imported devices
Indian manufacturers of medical devices have alleged that several private hospitals and retailers, in the chase for higher margins, are pushing sales of imported products, some of which carry inflated price tags or do not mention the maximum retail price (MRP). These imported devices of established brands account for about 65% of the medical devices sold in India, according to industry matter was discussed at a recent meeting with commerce and industry minister Piyush Goyal, industry executives told ET."It has been seen that the private hospitals and retailers preferentially push imported medical devices, often labelled with inflated or absent MRPs," a senior industry executive who attended the meeting told ET. "The hospitals are doing this to earn higher trade margins compared to affordable Indian made devices." The executive did not wish to be the meeting, representatives of domestic manufacturers discussed the procurement challenges the industry is facing in this regard. "They are making higher margins and more money. The consumer would bear the brunt and, hence, this issue was discussed during the meeting. The ministry has asked the NPPA (National Pharmaceutical Pricing Authority) to look into the matter," said another executive, requesting not to be named. Rajiv Nath, forum coordinator of Association of Indian Medical Device Industry (AiMeD), said domestic manufacturers face a stiff challenge in the market from imported devices despite offering the same product at rates that are 20-40% less, "as private hospitals and retailers are preferentially pushing imported established brands of medical devices, often carrying inflated prices or at times labels even without MRPs"."Indian manufacturers are forced to hike their labelled MRP to satisfy these buyers," he said domestic manufacturers have demanded that all import e-bills of lading should capture the import landed price as well as the MRP on the medical device, and any irrationally excessive MRP of 20 to 30 times of landed cost should be flagged for investigation for duty evasion and unfair trade practices.
